Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 Pipeline Review, H1 2018
Summary
Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 Tumor necrosis factor receptor superfamily member 9 TNFRSF9, also known as CD137 is a member of the tumor necrosis factor TNF receptor family. CD137 is expressed by activated T cells but to a larger extent on CD8 than on CD4 T cells. CD137 are involved in the regulation of a wide range of immune activities.
Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 17 and 4 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Metastatic Cancer, Metastatic Melanoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia CLL, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, NonHodgkin Lymphoma, NonSmall Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Thyroid Cancer, BCell Chronic Lymphocytic Leukemia, BCell NonHodgkin Lymphoma, Burkitt Lymphoma, Cervical Cancer, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Colorectal Cancer, Esophageal Cancer, Gliosarcoma, Lung Cancer, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma HCC, Nasopharyngeal Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal BCell Lymphoma, Recurrent Glioblastoma Multiforme GBM, Renal Cell Carcinoma, Sarcomas, SmallCell Lung Cancer and Thymoma Thymic Epithelial Tumor.
The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope